Peranteau William H, Heaton Todd E, Gu Yu-Chen, Volk Susan W, Bauer Thomas R, Alcorn Keith, Tuschong Laura M, Johnson Mark P, Hickstein Dennis D, Flake Alan W
Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Biol Blood Marrow Transplant. 2009 Mar;15(3):293-305. doi: 10.1016/j.bbmt.2008.11.034.
In the murine model, in utero hematopoietic cell transplantation (IUHCT) has been shown to achieve low levels of allogeneic chimerism and associated donor-specific tolerance permitting minimal conditioning postnatal hematopoietic stem cell transplantation (HSCT). In this pilot study, we investigated IUHCT in the canine leukocyte adhesion deficiency (CLAD) model. Haploidentical IUHCT resulted in stable low-level donor cell chimerism in all dogs that could be analyzed by sensitive detection methodology (4 of 10) through 18 months of follow-up. In the 2 CLAD recipients, low-level chimerism resulted in amelioration and complete reversal of the CLAD phenotype, respectively. Six recipients of IUHCT (5 carriers and 1 CLAD) subsequently received postnatal HSCT from the same haploidentical prenatal donor after minimal conditioning with busulfan 10 mg/kg. Chimerism in 2 of 5 CLAD carriers that underwent HSCT increased from < 1% pre-HSCT to sustained levels of 35% to 45%. Control animals undergoing postnatal haploidentical HSCT without IUHCT had no detectable donor chimerism. These results demonstrate that haploidentical IUHCT in the CLAD model can result in low-level donor chimerism that can prevent the lethal phenotype in CLAD dogs, and can result in donor-specific tolerance that can facilitate postnatal minimal conditioning HSCT.
在小鼠模型中,子宫内造血细胞移植(IUHCT)已被证明可实现低水平的异基因嵌合以及相关的供体特异性耐受,从而使出生后造血干细胞移植(HSCT)所需的预处理降至最低。在这项前瞻性研究中,我们在犬白细胞黏附缺陷(CLAD)模型中研究了IUHCT。单倍体IUHCT在所有可通过敏感检测方法进行分析的犬只(10只中的4只)中均导致了稳定的低水平供体细胞嵌合,随访时间长达18个月。在2只CLAD受体犬中,低水平嵌合分别导致CLAD表型的改善和完全逆转。6只IUHCT受体犬(5只携带者和1只CLAD)随后在接受10mg/kg白消安进行最低限度预处理后,从同一单倍体产前供体接受了出生后HSCT。5只接受HSCT的CLAD携带者中有2只的嵌合率从HSCT前的<1%增加到了35%至45%的持续水平。未进行IUHCT而接受出生后单倍体HSCT的对照动物未检测到供体嵌合。这些结果表明,CLAD模型中的单倍体IUHCT可导致低水平的供体嵌合,从而预防CLAD犬的致死表型,并可导致供体特异性耐受,从而促进出生后最低限度预处理的HSCT。